SecBot SecBot

Interagency Patent Coordination and Improvement Act of 2023

S. 79 Sen. Richard Durbin (D-IL) In committee
  1. Introduced Jan 25
  2. Committee Jan 25
  3. Passed Senate Next
  4. Passed House Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Jan 25, 2023Next: Senate vote
1337d ago Mar 1, 2023: Placed on Senate Legislative Calendar under General Orders. Calendar No. 18.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
5companies, 7 filings
Member trades
8trades in the last 90 days
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

5 companies
Companies by sector
Biotech & Pharma 5
Search all 5 companies, their asks and price moves Subscribe

Summary

Interagency Patent Coordination and Improvement Act of 2023

Full summary2 paragraphs

This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (PTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products.

The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the PTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the PTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the PTO, and (3) the PTO to assist the FDA in its ministerial role of listing patents.

Library of Congress summary, Mar 1, 2023

Summary versions
  • Reported to SenateMar 1, 2023
  • Introduced in SenateJan 25, 2023

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 27, 2026.